Vertex Pharmaceuticals said Tuesday that treatment with a combination of three cystic fibrosis drugs resulted in a statistically significant improvement in lung function for patients enrolled in two pivotal clinical trials.

With these positive data, the Boston-based biotech takes a step closer towards its long-stated goal of marketing new therapies capable of treating 90 percent of the genetic mutations that cause cystic fibrosis.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy